What is HC Wainwright’s Forecast for DTIL FY2026 Earnings?

Precision BioSciences, Inc. (NASDAQ:DTIL) – Equities research analysts at HC Wainwright boosted their FY2026 earnings estimates for Precision BioSciences in a note issued to investors on Thursday, November 5th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of ($2.01) per share for the year, up from their prior forecast of ($3.47). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Precision BioSciences’ current full-year earnings is ($2.60) per share. HC Wainwright also issued estimates for Precision BioSciences’ Q4 2026 earnings at ($0.72) EPS, Q1 2027 earnings at ($0.42) EPS, Q2 2027 earnings at ($0.43) EPS, Q3 2027 earnings at ($0.40) EPS, Q4 2027 earnings at ($0.41) EPS, FY2027 earnings at ($1.67) EPS, FY2028 earnings at ($0.85) EPS, FY2029 earnings at ($1.04) EPS and FY2030 earnings at $1.13 EPS.

Precision BioSciences (NASDAQ:DTIL) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.57. Precision BioSciences had a negative net margin of 96.73% and a negative return on equity of 56.69%.

A number of other equities analysts also recently commented on DTIL. Wall Street Zen upgraded shares of Precision BioSciences from a “sell” rating to a “hold” rating in a research note on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Precision BioSciences in a research note on Tuesday, November 3rd. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $32.25.

Precision BioSciences Price Performance

Precision BioSciences stock opened at $9.50 on Monday. The company has a fifty day simple moving average of $6.97 and a 200-day simple moving average of $6.67. Precision BioSciences has a 12-month low of $3.53 and a 12-month high of $11.29. The company has a quick ratio of 10.47, a current ratio of 10.47 and a debt-to-equity ratio of 0.43.

Institutional Investors Weigh In On Precision BioSciences

A number of institutional investors and hedge funds have recently made changes to their positions in DTIL. Affinity Asset Advisors LLC acquired a new stake in shares of Precision BioSciences during the first quarter worth about $3,289,000. Octagon Capital Advisors LP increased its position in Precision BioSciences by 16.6% in the 1st quarter. Octagon Capital Advisors LP now owns 2,236,732 shares of the company’s stock valued at $12,302,000 after acquiring an additional 318,737 shares during the period. Corient Private Wealth LP increased its position in Precision BioSciences by 70.4% in the 2nd quarter. Corient Private Wealth LP now owns 245,058 shares of the company’s stock valued at $1,926,000 after acquiring an additional 101,206 shares during the period. Squarepoint Ops LLC increased its position in Precision BioSciences by 212.7% in the 2nd quarter. Squarepoint Ops LLC now owns 137,106 shares of the company’s stock valued at $1,078,000 after acquiring an additional 93,258 shares during the period. Finally, Russell Investments Group Ltd. raised its stake in Precision BioSciences by 4,217.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 82,818 shares of the company’s stock valued at $518,000 after acquiring an additional 80,900 shares during the last quarter. 37.99% of the stock is owned by hedge funds and other institutional investors.

About Precision BioSciences

Precision BioSciences, Inc. is a biotechnology company developing gene-editing medicines using its proprietary ARCUS platform. ARCUS is based on engineered DNA-cutting enzymes designed to make targeted changes to genetic material, with the potential to remove, insert or correct DNA sequences in human cells. The company’s research and development activities have focused primarily on in vivo gene editing, in which therapeutic editing components are delivered directly into the body. Its development programs have included potential treatments for conditions such as chronic hepatitis B infection, Duchenne muscular dystrophy and certain rare genetic disorders.